

# Gavin J Churchyard

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4439853/gavin-j-churchyard-publications-by-citations.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

188  
papers

9,639  
citations

48  
h-index

94  
g-index

198  
ext. papers

11,378  
ext. citations

10.7  
avg, IF

5.8  
L-index

#	Paper	IF	Citations
188	The diarylquinoline TMC207 for multidrug-resistant tuberculosis. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 2397-405	59.2	613
187	The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. <i>European Respiratory Journal</i> , <b>2013</b> , 42, 1604-13	13.6	491
186	HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. <i>Lancet, The</i> , <b>2009</b> , 374, 921-33	40	349
185	Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. <i>Lancet, The</i> , <b>2014</b> , 383, 424-35	40	338
184	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. <i>Lancet Respiratory Medicine, the</i> , <b>2017</b> ,	35.1	313
183	High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1599-608	59.2	301
182	Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. <i>Lancet Infectious Diseases, The</i> , <b>2011</b> , 11, 507-15	25.5	272
181	Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. <i>PLoS Medicine</i> , <b>2011</b> , 8, e1000391	11.6	271
180	Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial. <i>Lancet, The</i> , <b>2010</b> , 376, 1244-53	40	207
179	High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. <i>Lancet Infectious Diseases, The</i> , <b>2017</b> , 17, 39-49	25.5	199
178	Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. <i>Lancet Infectious Diseases, The</i> , <b>2016</b> , 16, e34-46	25.5	190
177	Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. <i>Aids</i> , <b>2008</b> , 22, 1971-7	3.5	182
176	Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. <i>Lancet, The</i> , <b>2016</b> , 387, 1187-97	40	170
175	Achieving the health Millennium Development Goals for South Africa: challenges and priorities. <i>Lancet, The</i> , <b>2009</b> , 374, 1023-1031	40	165
174	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. <i>Lancet, The</i> , <b>2019</b> , 393, 1331-1384	43.84	158
173	A trial of mass isoniazid preventive therapy for tuberculosis control. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 301-10	59.2	157
172	Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. <i>Clinical Infectious Diseases</i> , <b>2002</b> , 34, 1251-8	11.6	154

171	Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. <i>The Lancet Global Health</i> , <b>2015</b> , 3, e450-e457	13.6	153
170	HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , <b>2015</b> , 349, aab1253	33.3	144
169	Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. <i>Lancet Infectious Diseases</i> , <b>2010</b> , 10, 489-98	25.5	142
168	Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2004</b> , 170, 673-9	10.2	136
167	HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. <i>Aids</i> , <b>2000</b> , 14, 2759-68	3.5	122
166	A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). <i>PLoS ONE</i> , <b>2011</b> , 6, e21225	3.7	120
165	Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection. <i>Nature Reviews Immunology</i> , <b>2018</b> , 18, 575-589	36.5	118
164	Epidemiology of HIV-associated tuberculosis. <i>Current Opinion in HIV and AIDS</i> , <b>2009</b> , 4, 325-33	4.2	118
163	Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. <i>Clinical Infectious Diseases</i> , <b>2008</b> , 47, 1479-85	11.6	108
162	"That is why I stopped the ART": patients' and providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. <i>BMC Public Health</i> , <b>2008</b> , 8, 63	4.1	106
161	Tuberculosis vaccines and prevention of infection. <i>Microbiology and Molecular Biology Reviews</i> , <b>2014</b> , 78, 650-71	13.2	103
160	Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. <i>The Lancet Global Health</i> , <b>2016</b> , 4, e806-e815	13.6	99
159	Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 49, 1928-35	11.6	98
158	What We Know About Tuberculosis Transmission: An Overview. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 216, S629-S635	7	97
157	Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. <i>Lancet</i> , <b>2010</b> , 375, 2179-91	40	91
156	Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. <i>PLoS Medicine</i> , <b>2007</b> , 4, e22	11.6	89
155	The economic burden of TB diagnosis and treatment in South Africa. <i>Social Science and Medicine</i> , <b>2015</b> , 130, 42-50	5.1	86
154	Towards host-directed therapies for tuberculosis. <i>Nature Reviews Drug Discovery</i> , <b>2015</b> , 14, 511-2	64.1	80

153	Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. <i>Lancet Infectious Diseases, The</i> , <b>2014</b> , 14, 388-96	25.5	80
152	Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2016</b> , 194, 1532-1540	10.2	71
151	Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. <i>PLoS ONE</i> , <b>2014</b> , 9, e89612	3.7	68
150	Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status. <i>Bulletin of the World Health Organization</i> , <b>2010</b> , 88, 13-21	8.2	63
149	Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. <i>Aids</i> , <b>2010</b> , 24 Suppl 5, S45-8	3.5	60
148	The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 34-41	11.6	56
147	Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 196 Suppl 1, S52-62	7	56
146	Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. <i>The Lancet Global Health</i> , <b>2016</b> , 4, e816-e826	13.6	56
145	Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study. <i>PLoS ONE</i> , <b>2013</b> , 8, e64459	3.7	53
144	Using Top-down and Bottom-up Costing Approaches in LMICs: The Case for Using Both to Assess the Incremental Costs of New Technologies at Scale. <i>Health Economics (United Kingdom)</i> , <b>2016</b> , 25 Suppl 1, 53-66	2.4	53
143	Advances in immunotherapy for tuberculosis treatment. <i>Clinics in Chest Medicine</i> , <b>2009</b> , 30, 769-82, ix	5.3	52
142	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 820-826	35.1	49
141	Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. <i>Journal of Virology</i> , <b>2010</b> , 84, 630-8	6.6	48
140	Tuberculosis Infectiousness and Host Susceptibility. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 216, S636-S643	7	46
139	HIV infection does not affect active case finding of tuberculosis in South African gold miners. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2009</b> , 180, 1271-8	10.2	45
138	The burden of silicosis, pulmonary tuberculosis and COPD among former Basotho goldminers. <i>American Journal of Industrial Medicine</i> , <b>2008</b> , 51, 640-7	2.7	45
137	Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation. <i>The Lancet Global Health</i> , <b>2017</b> , 5, e710-e719	13.6	44
136	Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis prevalence survey. <i>PLoS ONE</i> , <b>2012</b> , 7, e43307	3.7	44

135	Safety and immunogenicity of H1/IC31 $\square$ , an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm <sup>3</sup> : a phase II, multi-centre, double-blind, randomized, placebo-controlled trial. <i>PLoS ONE</i> , <b>2014</b> , 9, e114602	3.7	44
134	Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. <i>Aids</i> , <b>2010</b> , 24, 1051-5	3.5	43
133	High tuberculosis prevalence in a South African prison: the need for routine tuberculosis screening. <i>PLoS ONE</i> , <b>2014</b> , 9, e87262	3.7	43
132	Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 209, 711-20	7	42
131	Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. <i>BMC Infectious Diseases</i> , <b>2008</b> , 8, 93	4	40
130	Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug-resistant tuberculosis in South Africa. <i>BMC Infectious Diseases</i> , <b>2013</b> , 13, 352	4	39
129	Recurrent tuberculosis: relapse, reinfection, and HIV. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 201, 653-5	7	37
128	Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2012</b> , 61, 370-80	3.1	37
127	Four models of HIV counseling and testing: utilization and test results in South Africa. <i>PLoS ONE</i> , <b>2014</b> , 9, e102267	3.7	36
126	Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. <i>The Lancet Global Health</i> , <b>2019</b> , 7, e191-e199	13.6	35
125	Changing predictors of mortality over time from cART start: implications for care. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2011</b> , 58, 269-76	3.1	35
124	Undiagnosed tuberculosis among HIV clinic attendees: association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2012</b> , 60, e22-8	3.1	35
123	Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. <i>Lancet Infectious Diseases</i> , <b>2021</b> , 21, 354-365	25.5	34
122	Autopsy Prevalence of Tuberculosis and Other Potentially Treatable Infections among Adults with Advanced HIV Enrolled in Out-Patient Care in South Africa. <i>PLoS ONE</i> , <b>2016</b> , 11, e0166158	3.7	34
121	The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 448-55	5.1	33
120	Adverse events with isoniazid preventive therapy: experience from a large trial. <i>Aids</i> , <b>2010</b> , 24 Suppl 5, S29-36	3.5	33
119	Incidence of tuberculosis and HIV and progression of silicosis and lung function impairment among former Basotho gold miners. <i>American Journal of Industrial Medicine</i> , <b>2009</b> , 52, 901-8	2.7	33
118	Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204 Suppl 4, S1168-78	7	33

117	Cytomegalovirus viremia as a risk factor for mortality prior to antiretroviral therapy among HIV-infected gold miners in South Africa. <i>PLoS ONE</i> , <b>2011</b> , 6, e25571	3.7	32
116	Missed Opportunities for TB Investigation in Primary Care Clinics in South Africa: Experience from the XTEND Trial. <i>PLoS ONE</i> , <b>2015</b> , 10, e0138149	3.7	32
115	Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy. <i>American Journal of Epidemiology</i> , <b>2015</b> , 181, 619-32	3.8	31
114	Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 1072-1078	11.6	30
113	Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study. <i>BMC Public Health</i> , <b>2010</b> , 10, 433	4.1	30
112	Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. <i>Aids</i> , <b>2010</b> , 24 Suppl 5, S5-13	3.5	29
111	Genotype MTBDRplus for direct detection of Mycobacterium tuberculosis and drug resistance in strains from gold miners in South Africa. <i>Journal of Clinical Microbiology</i> , <b>2012</b> , 50, 1189-94	9.7	28
110	Mortality associated with delays between clinic entry and ART initiation in resource-limited settings: results of a transition-state model. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 63, 105-11	3.1	28
109	Thibela TB: design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis amongst gold miners in South Africa. <i>Contemporary Clinical Trials</i> , <b>2011</b> , 32, 382-92	2.3	28
108	Diagnostic accuracy of a urine lipoarabinomannan enzyme-linked immunosorbent assay for screening ambulatory HIV-infected persons for tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2011</b> , 58, 219-23	3.1	28
107	Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. <i>Aids</i> , <b>2010</b> , 24, 1709-16	3.5	28
106	Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study. <i>BMC Public Health</i> , <b>2010</b> , 10, 430	4.1	27
105	"Proof-of-concept" evaluation of an automated sputum smear microscopy system for tuberculosis diagnosis. <i>PLoS ONE</i> , <b>2012</b> , 7, e50173	3.7	26
104	The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm <sup>3</sup> . <i>Vaccine</i> , <b>2015</b> , 33, 1890-6	4.1	25
103	Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome. <i>PLoS ONE</i> , <b>2012</b> , 7, e36997	3.7	25
102	Incidence of HIV-associated tuberculosis among individuals taking combination antiretroviral therapy: a systematic review and meta-analysis. <i>PLoS ONE</i> , <b>2014</b> , 9, e111209	3.7	24
101	Contrasting reasons for discontinuation of antiretroviral therapy in workplace and public-sector HIV programs in South Africa. <i>AIDS Patient Care and STDs</i> , <b>2011</b> , 25, 53-9	5.8	23
100	The patient costs of care for those with TB and HIV: a cross-sectional study from South Africa. <i>Health Policy and Planning</i> , <b>2017</b> , 32, iv48-iv56	3.4	22

99	Performance of a Novel Algorithm Using Automated Digital Microscopy for Diagnosing Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2015</b> , 191, 1443-9	10.2	22
98	Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. <i>PLoS ONE</i> , <b>2015</b> , 10, e0137666	3.7	22
97	Trends in silicosis prevalence and the healthy worker effect among gold miners in South Africa: a prevalence study with follow up of employment status. <i>BMC Public Health</i> , <b>2015</b> , 15, 1258	4.1	21
96	A clinical scoring system to prioritise investigation for tuberculosis among adults attending HIV clinics in South Africa. <i>PLoS ONE</i> , <b>2017</b> , 12, e0181519	3.7	21
95	Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial. <i>Lancet HIV,the</i> , <b>2020</b> , 7, e27-e37	7.8	21
94	Symptom and chest radiographic screening for infectious tuberculosis prior to starting isoniazid preventive therapy: yield and proportion missed at screening. <i>Aids</i> , <b>2010</b> , 24 Suppl 5, S19-27	3.5	19
93	Measuring mortality due to HIV-associated tuberculosis among adults in South Africa: Comparing verbal autopsy, minimally-invasive autopsy, and research data. <i>PLoS ONE</i> , <b>2017</b> , 12, e0174097	3.7	18
92	Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection. <i>PLoS Pathogens</i> , <b>2018</b> , 14, e1006888	7.6	18
91	Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. <i>Tuberculosis</i> , <b>2018</b> , 109, 61-68	2.6	18
90	Controlling latent TB tuberculosis infection in high-burden countries: A neglected strategy to end TB. <i>PLoS Medicine</i> , <b>2019</b> , 16, e1002787	11.6	17
89	An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	17
88	Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 915-20	1.6	17
87	Diagnostic Accuracy of Lateral Flow Urine LAM Assay for TB Screening of Adults with Advanced Immunosuppression Attending Routine HIV Care in South Africa. <i>PLoS ONE</i> , <b>2016</b> , 11, e0156866	3.7	16
86	Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. <i>Lancet HIV,the</i> , <b>2020</b> , 7, e401-e409	7.8	16
85	Strategies to Accelerate HIV Care and Antiretroviral Therapy Initiation After HIV Diagnosis: A Randomized Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 75, 540-547	3.1	15
84	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. <i>PLoS ONE</i> , <b>2015</b> , 10, e0136626	3.7	15
83	Aspiring to zero tuberculosis deaths among southern Africa miners: is there a way forward?. <i>International Journal of Health Services</i> , <b>2013</b> , 43, 651-64	2	15
82	A novel HIV treatment model using private practitioners in South Africa. <i>Sexually Transmitted Infections</i> , <b>2012</b> , 88, 136-40	2.8	15

81	Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. <i>PLoS Medicine</i> , <b>2017</b> , 14, e1002202	11.6	15
80	TB sequel: incidence, pathogenesis and risk factors of long-term medical and social sequelae of pulmonary TB - a study protocol. <i>BMC Pulmonary Medicine</i> , <b>2019</b> , 19, 4	3.5	15
79	Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 897-908	35.1	15
78	Tuberculosis preventive therapy: an underutilised strategy to reduce individual risk of TB and contribute to TB control. <i>South African Medical Journal</i> , <b>2014</b> , 104, 339-43	1.5	14
77	Twelve-monthly versus six-monthly radiological screening for active case-finding of tuberculosis: a randomised controlled trial. <i>Thorax</i> , <b>2011</b> , 66, 134-9	7.3	14
76	The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study. <i>BMC Medicine</i> , <b>2016</b> , 14, 45	11.4	13
75	Using mHealth to improve tuberculosis case identification and treatment initiation in South Africa: Results from a pilot study. <i>PLoS ONE</i> , <b>2018</b> , 13, e0199687	3.7	13
74	What is thwarting tuberculosis prevention in high-burden settings?. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 79-81	59.2	13
73	Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): study protocol for a cluster randomised controlled trial. <i>Trials</i> , <b>2015</b> , 16, 125	2.8	12
72	Tuberculosis prevention in South Africa. <i>PLoS ONE</i> , <b>2015</b> , 10, e0122514	3.7	12
71	Expanding HIV care in Africa: making men matter in Johannesburg. <i>Lancet, The</i> , <b>2009</b> , 374, 1329	40	12
70	Pan-tuberculosis regimens: an argument for. <i>Lancet Respiratory Medicine</i> , <b>2018</b> , 6, 239-240	35.1	11
69	Research Roadmap for Tuberculosis Transmission Science: Where Do We Go From Here and How Will We Know When We're There?. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 216, S662-S668	7	11
68	Clinical Relevance of Nontuberculous Mycobacteria Isolated from Sputum in a Gold Mining Workforce in South Africa: An Observational, Clinical Study. <i>BioMed Research International</i> , <b>2015</b> , 2015, 959107	3	11
67	Molecular epidemiology of Mycobacterium tuberculosis among South African gold miners. <i>Annals of the American Thoracic Society</i> , <b>2015</b> , 12, 12-20	4.7	11
66	A trial of mass isoniazid preventive therapy for tuberculosis control. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 1662-3	59.2	11
65	The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis. <i>PLoS Medicine</i> , <b>2015</b> , 12, e1001869	11.6	11
64	Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. <i>PLoS ONE</i> , <b>2016</b> , 11, e0161753	3.7	11



63	Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. <i>The Lancet Global Health</i> , <b>2021</b> , 9, e841-e853	13.6	11
62	Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study. <i>Tropical Medicine and International Health</i> , <b>2014</b> , 19, 236-9	2.3	10
61	Household HIV Testing Uptake among Contacts of TB Patients in South Africa. <i>PLoS ONE</i> , <b>2016</b> , 11, e0155688	3.7	10
60	Implementing a large-scale systematic tuberculosis screening program in correctional facilities in South Africa. <i>Open Forum Infectious Diseases</i> , <b>2015</b> , 2, ofu121	1	9
59	Empiric tuberculosis treatment in South African primary health care facilities - for whom, where, when and why: Implications for the development of tuberculosis diagnostic tests. <i>PLoS ONE</i> , <b>2018</b> , 13, e0191608	3.7	9
58	The diagnostic accuracy of urine lipoarabinomannan test for tuberculosis screening in a South African correctional facility. <i>PLoS ONE</i> , <b>2015</b> , 10, e0127956	3.7	9
57	Team up against TB promoting involvement in Thibela TB, a trial of community-wide tuberculosis preventive therapy. <i>Aids</i> , <b>2010</b> , 24 Suppl 5, S37-44	3.5	9
56	Patient costs incurred by people living with HIV/AIDS prior to ART initiation in primary healthcare facilities in Gauteng, South Africa. <i>PLoS ONE</i> , <b>2019</b> , 14, e0210622	3.7	8
55	Heat Inactivation Renders Sputum Safe and Preserves RNA for Downstream Molecular Tests. <i>Journal of Clinical Microbiology</i> , <b>2019</b> , 57,	9.7	8
54	Molecular characterisation of clinical and environmental isolates of <i>Mycobacterium kansasii</i> isolates from South African gold mines. <i>Journal of Water and Health</i> , <b>2015</b> , 13, 190-202	2.2	8
53	Predictors of silicosis and variation in prevalence across mines among employed gold miners in South Africa. <i>BMC Public Health</i> , <b>2020</b> , 20, 829	4.1	8
52	Guidance for Studies Evaluating the Accuracy of Sputum-Based Tests to Diagnose Tuberculosis. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 220, S99-S107	7	8
51	Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women. <i>PLoS ONE</i> , <b>2012</b> , 7, e31387	3.7	8
50	HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa. <i>Aids</i> , <b>2009</b> , 23, 1784-6	3.5	8
49	Cost-Effectiveness of Automated Digital Microscopy for Diagnosis of Active Tuberculosis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0157554	3.7	8
48	Clinic-level factors influencing patient outcomes on antiretroviral therapy in primary health clinics in South Africa. <i>Aids</i> , <b>2016</b> , 30, 1099-109	3.5	8
47	Protein binding of rifampicin is not saturated when using high-dose rifampicin. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 986-990	5.1	8
46	A stratified approach to tuberculosis treatment. <i>Nature Medicine</i> , <b>2018</b> , 24, 1639-1641	50.5	8

45	Outcomes of on-site antiretroviral therapy provision in a South African correctional facility. <i>International Journal of STD and AIDS</i> , <b>2016</b> , 27, 1153-1161	1.4	7
44	Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4+ T Cells. <i>Vaccine Journal</i> , <b>2015</b> , 22, 688-96		7
43	Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses. <i>PLoS ONE</i> , <b>2014</b> , 9, e103446	3.7	7
42	Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. <i>European Respiratory Journal</i> , <b>2021</b> , 58,	13.6	7
41	Small contribution of gold mines to the ongoing tuberculosis epidemic in South Africa: a modeling-based study. <i>BMC Medicine</i> , <b>2018</b> , 16, 52	11.4	6
40	Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality?: did close examination of the trees obscure our view of the wood?. <i>Aids</i> , <b>2010</b> , 24 Suppl 5, S15-8	3.5	6
39	Verbal autopsy-assigned causes of death among adults being investigated for TB in South Africa. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , <b>2016</b> , 110, 510-516	2	6
38	The incidence of tuberculosis among hiv-positive individuals with high CD4 counts: implications for policy. <i>BMC Infectious Diseases</i> , <b>2016</b> , 16, 266	4	6
37	Impact of Targeted Tuberculosis Vaccination Among a Mining Population in South Africa: A Model-Based Study. <i>American Journal of Epidemiology</i> , <b>2017</b> , 186, 1362-1369	3.8	5
36	Brief Report: The Effect of Antiretroviral Therapy and CD4 Count on Markers of Infectiousness in HIV-Associated Tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2015</b> , 70, 104-8	3.1	5
35	The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants. <i>International Journal of STD and AIDS</i> , <b>2014</b> , 25, 332-40	1.4	5
34	Eligibility for isoniazid preventive therapy in South African gold mines. <i>PLoS ONE</i> , <b>2013</b> , 8, e81376	3.7	5
33	Uptake of genital mucosal sampling in HVTN 097, a phase 1b HIV vaccine trial in South Africa. <i>PLoS ONE</i> , <b>2014</b> , 9, e112303	3.7	5
32	Household point of care CD4 testing and isoniazid preventive therapy initiation in a household TB contact tracing programme in two districts of South Africa. <i>PLoS ONE</i> , <b>2018</b> , 13, e0192089	3.7	5
31	Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis. <i>PLoS Medicine</i> , <b>2021</b> , 18, e1003738	11.6	5
30	Application of provincial data in mathematical modelling to inform sub-national tuberculosis program decision-making in South Africa. <i>PLoS ONE</i> , <b>2019</b> , 14, e0209320	3.7	4
29	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. <i>Npj Vaccines</i> , <b>2021</b> , 6, 56	9.5	4
28	Performance of verbal autopsy methods in estimating HIV-associated mortality among adults in South Africa. <i>BMJ Global Health</i> , <b>2018</b> , 3, e000833	6.6	4

27	Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. <i>MSphere</i> , <b>2020</b> , 5,	5	3
26	Monitoring Anti-tuberculosis Treatment Response Using Analysis of Whole Blood Specific T Cell Activation and Functional Markers. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 572620	8.4	3
25	Tuberculosis active case finding: uptake and diagnostic yield among minibus drivers in urban South Africa. <i>BMC Public Health</i> , <b>2015</b> , 15, 242	4.1	2
24	Linkage to care among adults being investigated for tuberculosis in South Africa: pilot study of a case manager intervention. <i>BMJ Open</i> , <b>2018</b> , 8, e021111	3	2
23	Opportunities afforded by new drugs for tuberculosis. <i>Lancet Infectious Diseases, The</i> , <b>2010</b> , 10, 368-9	25.5	2
22	Plasma host protein biomarkers correlating with increasing Mycobacterium tuberculosis infection activity prior to tuberculosis diagnosis in people living with HIV.. <i>EBioMedicine</i> , <b>2021</b> , 75, 103787	8.8	2
21	Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. <i>Scientific Reports</i> , <b>2020</b> , 10, 13031	4.9	2
20	Strengthening health systems to improve the value of tuberculosis diagnostics in South Africa: A cost and cost-effectiveness analysis. <i>PLoS ONE</i> , <b>2021</b> , 16, e0251547	3.7	2
19	Neutrophils contribute to severity of tuberculosis pathology and recovery from lung damage pre- and post-treatment. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,	11.6	2
18	Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR.. <i>Communications Medicine</i> , <b>2022</b> , 2,		2
17	Tuberculosis: The global killer. <i>South African Journal of Science</i> , <b>2013</b> , 109, 1-2	1.3	1
16	Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis. <i>Lancet Infectious Diseases, The</i> , <b>2021</b> ,	25.5	1
15	Causes and Outcomes of Admission and Investigation of Tuberculosis in Adults with Advanced HIV in South African Hospitals: Data from the TB Fast Track Trial. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2021</b> ,	3.2	1
14	Cost-effectiveness of a 12 country-intervention to scale up short course TB preventive therapy among people living with HIV. <i>Journal of the International AIDS Society</i> , <b>2020</b> , 23, e25629	5.4	1
13	Seroprevalence of -Specific IgG Antibody among Mozambican Tuberculosis Patients. <i>Journal of Fungi (Basel, Switzerland)</i> , <b>2021</b> , 7,	5.6	1
12	Adaptation of WHO® generic tuberculosis patient cost instrument for a longitudinal study in Africa. <i>Global Health Action</i> , <b>2021</b> , 14, 1865625	3	0
11	Sub-Lineage Specific Phenolic Glycolipid Patterns in the Complex Lineage 1.. <i>Frontiers in Microbiology</i> , <b>2022</b> , 13, 832054	5.7	0
10	The effect of host factors on discriminatory performance of a transcriptomic signature of tuberculosis risk.. <i>EBioMedicine</i> , <b>2022</b> , 77, 103886	8.8	0

- 9 Mycobacterium tuberculosis infection, immune activation, and risk of HIV acquisition.. *PLoS ONE*, **2022**, 17, e0267729 3.7 0
- 8 Regarding the effect of cured tuberculosis disease on longevity. *International Journal of Tuberculosis and Lung Disease*, **2015**, 19, 367 2.1
- 7 Improved services to enrollees into an HIV rural care and treatment center in Tanzania. *Pan African Medical Journal*, **2013**, 16, 34 1.2
- 6 Tuberculosis and HIV457-478
- 5 Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa: authorsOreply. *Aids*, **2009**, 23, 872-873 3.5
- 4 An ecological study to evaluate the association of Bacillus Calmette-Guerin (BCG) vaccination on cases of SARS-CoV2 infection and mortality from COVID-19 **2020**, 15, e0243707
- 3 An ecological study to evaluate the association of Bacillus Calmette-Guerin (BCG) vaccination on cases of SARS-CoV2 infection and mortality from COVID-19 **2020**, 15, e0243707
- 2 An ecological study to evaluate the association of Bacillus Calmette-Guerin (BCG) vaccination on cases of SARS-CoV2 infection and mortality from COVID-19 **2020**, 15, e0243707
- 1 An ecological study to evaluate the association of Bacillus Calmette-Guerin (BCG) vaccination on cases of SARS-CoV2 infection and mortality from COVID-19 **2020**, 15, e0243707